Medplus Health Services Ltd Q4 FY2025 Concall Summary

Key Takeaways

• Growth muted by private label push: Pharmacy GMV grew only 6.2% in Q4 as the company’s deliberate focus on private label cannibalized branded sales, dragging same-store revenue into negative territory.
• Gross margin got a one-time lift: Q4 gross margin benefited from a ~₹3 cr inventory provision release (~20 bps) tied to old Wynclark products that were sold during the quarter.
• Store rollout halved, now reset: The company added roughly half its planned 600 stores in FY25, slowed by elections, high attrition in South Indian cities, and supply chain gaps it is now fixing with new warehouses.
• Diagnostics turned the corner: The segment swung from an operating EBITDA loss of ₹1.13 cr in Q4 FY24 to a profit of ₹3.43 cr in Q4 FY25, though subscriber growth remains well below the threshold needed for state expansion.
• What to watch next quarter: Whether same-store sales return to positive territory now that the private label incentive realignment is done, the pace of new store openings against the 600-store target, and any quantification of the selling-cost drag from employee incentives.

Private Label: The Growth-Margin Tradeoff

• Mix shift muted top-line growth: Private label products sell at lower prices than branded equivalents, so the rapid mix shift from 7.9% of GMV in Q1 FY24 to 20.9% in Q4 FY25 mechanically depressed reported revenue growth even as unit volumes grew.
• Branded sales were cannibalized: Employee incentives tied to private label sales caused a small but real drag on branded product sales, contributing to the ~1% same-store revenue decline in Q4. Management now considers the organizational buy-in achieved and is realigning incentives to both categories.
• Future private label growth to slow: Early adopters have already converted; management expects private label share to expand by roughly 1% per quarter going forward, with Q1 likely "slightly flattish." Substitution of brands is not expected to be very high from here.
• The ceiling is far below 90%: Management would like private label to reach 90% but expects it to settle much lower because some brands remain cheaper despite the discount, certain products have no substitutes (insulins, patented drugs), and the share of patented products is rising.
• GLP-1 opportunity targeted for patent expiry: The company is already in discussions with potential partners and aims to launch a private label GLP-1 product on day one or month one of the March 2026 patent expiry.

Madhukar Reddy: "I would like it to go all the way to 90%. But the thing is it will probably settle down at a much lower number, mainly because of 2 things."

Store Network & Warehouse Buildout

• Store addition fell short in FY25: The company planned 600 new stores but closed at roughly half, citing Q1 election disruptions, worker shortages, high attrition in larger South Indian cities, and supply chain delays to remote areas served from distant main warehouses.
• Warehouse densification is the fix: New warehouses in cities like Madurai and Hubli are meant to create 2–3 nodes per state instead of one, solving fill-rate problems for remote stores (e.g., Bangalore supplying up to Udupi and Mangalore). Only one of the ten new warehouses (Calcutta) is functional as of the call; the rest ramp up over the next few quarters.
• 600-store target reinstated for FY26: The company plans 600 net store additions in the coming year, spread throughout the year with Q1 likely lighter. A franchisee pilot is underway where MedPlus acts as super-distributor to franchisee-owned MedPlus-branded stores, reducing the company’s investment and people-management burden.
• New store breakeven is fast: 58% of stores opened between April and September 2024 achieved breakeven within six months; the entire cohort reached breakeven in five months. Stores older than 24 months deliver 11.7% EBITDA margin versus 8.2% for the 13–24 month bracket.
• Delhi/NCR pilot is limited in scope: Stores opened in Noida, Gurgaon, and Delhi are testing online delivery within Delhi city only; there is no intention to enter Haryana, UP, or Delhi state broadly.
• New state expansion unchanged: Madhya Pradesh, Chhattisgarh, and Kerala remain the planned states for the next three years. Kerala is on a wait-and-watch approach with only a few stores, as the company wants to ensure profitability and find the right model first.

Madhukar Reddy: "I think we will be back on track given that the new store numbers are going to be much less compared to the overall size of the company itself and stores also will sort of get phased out throughout the year."

Margins & Cost Structure

• Gross margin guided higher: Pharmacy gross margin is guided to 24.5%–24.8% going forward, up from ~24.1% for the full year FY25. The Q4 print included a ~20 bps benefit from a ₹3 cr inventory provision release on old Wynclark products.
• Operating EBITDA margin target set: Management expects pharmacy operating EBITDA margin to cross 5% in the next two years, driven by private label benefits and a lower drag from new stores given the smaller addition numbers.
• Employee costs are rising on two fronts: The increase reflects private label selling incentives (booked as salary expense under accounting rules) and a store-level employee retention plan introduced a couple of quarters ago. The incentive cost is dynamic, adjusted quarterly, and management declined to quantify it on the call.
• Warehouse benefits are back-end loaded: Most new warehouses come online in the next few quarters, with cost benefits expected to materialize only in the next year.
• Tax rate stays low: The company expects its tax rate to remain below 25% as long as the Section 80JJAA deduction is available, given continued employee additions.

Madhukar Reddy: "The number of stores we are adding are not very significant. So the drag of the new stores is not going to be significant. But I think we'll continue to get the benefit of private label. So that should basically help us expand the margin."

Diagnostics: Profitable but Sub-Scale

• Turnaround delivered: The diagnostics segment moved from an operating EBITDA loss of ₹1.13 cr in Q4 FY24 to a profit of ₹3.43 cr in Q4 FY25, with revenue growing from ₹23.24 cr to ₹28 cr.
• Subscriber growth is too slow: Active plans grew by only 5,000 in the quarter to 157,000, covering 327,000 lives. Management acknowledges this is much lower than desired and that roughly 250,000 active plans are needed before expanding diagnostics to other states.
• Home collection capacity is constrained: Online slots are based on headcount, and active members want more home pickup slots than are currently available. Hiring is incremental as demand grows, and home service staff are separate from store staff.

Franchisee Model & Promoter Commentary

• Franchisee pilot underway: The model is wholesale: MedPlus sells product to the franchisee as a super-distributor, and the franchisee sells to end customers under the MedPlus brand. The company believes improved margins now allow it to share economics with franchisees while reducing its own investment and people-management burden.
• No near-term promoter stake sale: Management has no plans to sell shares in the near future. If any sale were to occur, it would be mainly to clear debt or for refinancing.

Madhukar Reddy: "3 to 4 years is a long time. I'm not really thinking about it right now, but I don't expect to sell any shares in the near future at least."

Data Gaps & Unanswered Questions

• Q4 GMV growth not disclosed: When asked for the Q4 GMV growth figure, management said it would get back to the analyst and did not provide the number during the call.
• Same-store decline not decomposed: Management attributed the ~1% same-store revenue decline to private label mix and incentive-driven branded cannibalization but did not quantify the split between the two factors.
• Private label share by state not available: Management offered general color (Tier 3/4 higher than Tier 1; Mumbai lowest at ~10–11%) but said exact numbers were not on hand.
• Store count by tier not precise: When asked for the number of stores in Tier 2 and beyond, management estimated "around 40%" but said it would confirm later.
• Selling-cost quantification declined: The employee incentive cost tied to private label was not quantified; management described it as a dynamic quarterly exercise and offered to take the discussion offline.

Guidance & Commitments

Key Metrics